Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Montes, R. (Ramón) | - |
dc.creator | Ruiz-de-Gaona, E. (Estefanía) | - |
dc.creator | Martinez-Gonzalez, M.A. (Miguel Ángel) | - |
dc.creator | Alberca, I. (Ignacio) | - |
dc.creator | Hermida, J. (José) | - |
dc.date.accessioned | 2012-05-11T10:52:55Z | - |
dc.date.available | 2012-05-11T10:52:55Z | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol 2006 Apr;133(2):183-187. | es_ES |
dc.identifier.issn | 1365-2141 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21989 | - |
dc.description.abstract | Much of the variability in the sensitivity to warfarin in anticoagulated patients is associated with the c.-1639G > A polymorphism of the vitamin K-epoxide reductase (VKORC1) gene. However, its association with the acenocoumarol dose in patients under anticoagulant therapy has not been studied. The c.-1639G > A genotype of VKORC1 was determined in 113 patients on stable anticoagulation requiring low (n = 42), medium (n = 42) or high (n = 21) acenocoumarol doses. To evaluate the association between acenocoumarol requirements and the c.-1639G > A variant, multivariate logistic regression models were fitted, adjusting for age, gender, and the c.430C > T and c.1075A > C variants of cytochrome P450 2C9 (CYP2C9). A total of 90.5% of the patients in the low acenocoumarol dose group carried the A allele of VKORC1:c.-1639G > A. The A allele independently increased the odds of requiring a low acenocoumarol dose [odds ratio (OR) 9.4; 95% confidence interval (CI) 1.9-46.4; P = 0.006], especially when the homozygous form was present (OR 44.2; 95% CI 5.5-354.6; P < 0.001). The A allele was less frequent in the high dose group showing an inverse association with the requirement for high doses (OR 0.04; 95% CI 0.01-0.22; P < 0.001). The A allele of the c.-1639G > A polymorphism of VKORC1 is therefore associated with a low-dose requirement for acenocoumarol in patients receiving anticoagulant therapy. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Blackwell Publishing | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Vitamin K | es_ES |
dc.subject | Drugs | es_ES |
dc.subject | Anticoagulation | es_ES |
dc.title | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2006.06007.x/abstract | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.